Allergan Biocell Textured Breast Implant

The Allergan Biocell textured breast implant docket, centered on claims linking a textured implant surface to breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), a rare cancer of the immune system, carries 1,370 pending actions six years after centralization. Claims in this docket span a meaningful range of severity and posture — from implant-removal (explant) and monitoring claims by patients who have not developed lymphoma but face ongoing surveillance and anxiety damages, to claims by patients diagnosed with BIA-ALCL who have undergone cancer treatment, to wrongful-death claims in the most severe cases.

For a funder, that severity spread is the central diligence question in this docket: a claim's value and litigation strength differ substantially depending on whether it involves a confirmed BIA-ALCL diagnosis with associated oncology treatment versus an explant or surveillance-only claim without a cancer diagnosis. Portfolio-level inventory finance can work here for a firm with meaningful volume, but underwriting needs to segment the book by diagnosis status and treatment severity rather than pricing the portfolio as a single undifferentiated population.

Medical-lien considerations are significant for the diagnosed-cancer subset of claims, given the oncology treatment, surgical, and monitoring costs typically involved, and comparatively minimal for the explant-only or surveillance claim population, which further supports segmenting any financing structure by claim severity.

Given the docket's meaningful size and the years of device-and-causation discovery already developed around the BIA-ALCL link, this is a docket where both single-case and segmented portfolio financing can be appropriate depending on a firm's specific inventory composition. Criterica Capital's mass-tort finance and medical-lien receivables products both apply depending on where a given claim sits on that severity spectrum.

Criterica Intelligence's structural brief on this docket covers the diagnosis-versus-surveillance claim distinction in more depth.

Pre-settlement funding is a non-recourse purchase of a portion of the proceeds of a pending legal claim — not a loan. If the case does not result in a recovery, nothing is owed. Rates, fees, and repayment terms are disclosed in full in the funding agreement, which the applicant’s attorney reviews before signing. Availability and terms vary by state.